GSK
GSK
718 hedge funds and large institutions have $8.72B invested in GSK in 2015 Q4 according to their latest regulatory filings, with 93 funds opening new positions, 233 increasing their positions, 274 reducing their positions, and 69 closing their positions.
85% more call options, than puts
Call options by funds: $221M | Put options by funds: $120M
35% more first-time investments, than exits
New positions opened: 93 | Existing positions closed: 69
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
2% more funds holding
Funds holding: 706 → 718 (+12)
2% more capital invested
Capital invested by funds: $8.53B → $8.72B (+$189M)
0.12% less ownership
Funds ownership: 3.66% → 3.54% (-0.12%)
15% less repeat investments, than reductions
Existing positions increased: 233 | Existing positions reduced: 274
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$93.9M |
| 2 |
Jane Street
New York
|
+$48.6M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$34.4M |
| 4 |
JHC
JFB Holdings Corp
Atlanta,
Georgia
|
+$32.6M |
| 5 |
Citigroup
New York
|
+$23.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$129M |
| 2 |
JP Morgan Chase
New York
|
-$57.8M |
| 3 |
Renaissance Technologies
New York
|
-$51.1M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$32.6M |
| 5 |
O
OppenheimerFunds
New York
|
-$30.9M |
GSK Hedge Fund Activity: Q4 2015 in Review
718 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q4 2015, worth a combined $8.72B — up 2.2% from $8.53B a quarter earlier.
Buyers outnumbered sellers: 93 funds opened new GSK positions and 69 closed out — a net gain of 24 holders — while 233 added to existing stakes and 274 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $93.9M. The largest seller was Arrowstreet Capital, cutting an estimated $129M.
- 718 institutional investors held GSK (GSK) as of Q4 2015, up from 706 in Q3 2015.
- Funds reported $8.72B of GSK stock for Q4 2015, up 2.2% quarter-over-quarter.
- 93 funds opened new GSK positions in Q4 2015 and 69 closed out, a net change of +24 holders.
- The largest GSK buyer in Q4 2015 was Fidelity Investments, an estimated $93.9M added.
- The largest GSK seller in Q4 2015 was Arrowstreet Capital, an estimated $129M sold.
Based on aggregated 13F filings for Q4 2015.